Exelixis (EXEL) shares are in focus after the company reported final subgroup data from its phase 3 STELLAR-303 trial of zanzalintinib plus atezolizumab in metastatic colorectal cancer without active liver metastases.

Against this clinical backdrop, Exelixis has also been on the move in the market, with the latest share price at $53.23 and a 90 day share price return of 28.17% alongside a 5 year total shareholder return of 185.57%. This suggests investors are reacting to both near term trial updates and the broader pipeline story.

If this kind of oncology pipeline news has your attention, it could be a good time to see what else is on the move in cancer and biotech by scanning 39 healthcare AI stocks

With Exelixis now trading above the average analyst price target but showing a large intrinsic value gap, is the recent rally already baking in zanzalintinib’s potential, or is the market still underrating its future prospects?

Most Popular Narrative: 7.2% Overvalued

With Exelixis trading at $53.23 against a most-followed fair value estimate of about $49.65, the current share price sits above that narrative anchor yet still reflects a business backed by active oncology programs and large reported valuation headroom from cash flow models.

The company's substantial free cash flow, strong balance sheet, and disciplined capital allocation (including aggressive share repurchases and prioritization of high-probability, high-value R&D programs) position Exelixis to invest in next-generation discovery and strategic partnerships, which has the potential to improve operating leverage and net margins over time as the product portfolio scales.

Curious what underpins that fair value call for Exelixis? The narrative emphasizes the company’s current revenue profile, margin structure, and the relationship between today’s market price and the earnings multiple implied by that fair value estimate. The discussion centers on how earnings are modeled in the valuation work and how much profit per share is attributed to share repurchases in those models.

Result: Fair Value of $49.65 (OVERVALUED)

However, if Exelixis' heavy reliance on CABOMETYX and exposure to pricing and reimbursement pressures worsen, these headwinds could still upset this fair value narrative.

Another View on Exelixis Valuation

While the most-followed fair value of $49.65 points to Exelixis looking about 7.2% overvalued, the SWS DCF model tells a very different story, with an estimated future cash flow value of $217.90 per share that suggests a very large valuation gap in the other direction.

If one framework flags modest overvaluation and another flags substantial potential undervaluation, it puts the spotlight on which assumptions about growth, margins, and duration of cash flows you find more realistic.

Next Steps

With sentiment on Exelixis split between upside potential and meaningful risks, this is a moment to move quickly and weigh the trade off yourself by checking the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Exelixis?

If Exelixis has sharpened your interest, do not stop there. Use the Simply Wall Street screener to uncover other opportunities that might suit your investing style.

• Target stronger value potential by scanning companies that currently look mispriced using the 43 high quality undervalued stocks.
• Prioritize capital preservation and steadier profiles with the 67 resilient stocks with low risk scores before committing to your next position.
• Hunt for underfollowed opportunities by checking the screener containing 19 high quality undiscovered gems so you are not the last to spot a compelling idea.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.